Antonio Peón

Antonio Peón

Auto-generated profile, based on publicly available information

Antonio Peón

Centro Singular de Investigacion en Quimica Biologica y Materiales Moleculares (CIQUS), Universidad de Santiago de Compostela, 15782 Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
APAntonio Peón
Antonio Peón
SNStefan Naulaerts
Stefan Naulaerts
Pedro BallesterPedro Ballester
Pedro Ballester
Many computational methods to predict the macromolecular targets of small organic molecules have been presented to date. Despite progress, target prediction methods still have important limitations. For example, the most accurate methods implicitly restrict their predictions to a relatively small number of targets, are not systematically validated on drugs (whose targets are harder to predict than those of non-drug molecules) and often lack a reliability score associated with each predicted target. Here we present a systematic validation of ligand-centric target prediction methods on a set of clinical drugs. These methods exploit a knowledge-base covering 887,435 known ligand-target associations between 504,755 molecules and 4,167 targets. Based on this dataset, we provide a new estimate of the polypharmacology of drugs, which on average have 11.5 targets below IC50 10 µM. The average performance achieved across clinical drugs is remarkable (0.348 precision and 0.423 recall, with large drug-dependent variability), especially given the unusually large coverage of the target space. Furthermore, we show how a sparse ligand-target bioactivity matrix to retrospectively validate target prediction methods could underestimate prospective performance. Lastly, we present and validate a first-in-kind score capable of accurately predicting the reliability of target predictions.

27 March 2019 in Chemical Biology & Drug Design
Verified
Journal Article
Closed access
PDF file
APAntonio Peón
Antonio Peón
HLHongjian Li
Hongjian Li
GGGhita Ghislat
Ghita Ghislat
KLKwong‐Sak Leung
Kwong‐Sak Leung
MWMan‐Hon Wong
Man‐Hon Wong
Pedro BallesterPedro Ballester
Pedro Ballester

14 April 2016 in Frontiers in Chemistry
Verified
Journal Article
Open access
PDF file
APAntonio Peón
Antonio Peón
CDCuong C. Dang
Cuong C. Dang
Pedro BallesterPedro Ballester
Pedro Ballester
Computational methods for Target Fishing (TF), also known as Target Prediction or Polypharmacology Prediction, can be used to discover new targets for small-molecule drugs. This may result in repositioning the drug in a new indication or improving our current understanding of its efficacy and side effects. While there is a substantial body of research on TF methods, there is still a need to improve their validation, which is often limited to a small part of the available targets and not easily interpretable by the user. Here we discuss how target-centric TF methods are inherently limited by the number of targets that can possibly predict (this number is by construction much larger in ligand-centric techniques). We also propose a new benchmark to validate TF methods, which is particularly suited to analyse how predictive performance varies with the query molecule. On average over approved drugs, we estimate that only five predicted targets will have to be tested to find two true targets with submicromolar potency (a strong variability in performance is however observed). In addition, we find that an approved drug has currently an average of eight known targets, which reinforces the notion that polypharmacology is a common and strong event. Furthermore, with the assistance of a control group of randomly-selected molecules, we show that the targets of approved drugs are generally harder to predict.

2 September 2010 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
APAntonio Peón
Antonio Peón
JOJosé M. Otero
José M. Otero
LTLorena Tizón
Lorena Tizón
VPVerónica F. V. Prazeres
Verónica F. V. Prazeres
ALAntonio Luis Llamas-Saiz
Antonio Luis Llamas-Saiz
Concepción González-BelloConcepción González-Bello
Concepción González-Bello

5 March 2012 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
BBBeatriz Blanco
Beatriz Blanco
ASAntía Sedes
Antía Sedes
APAntonio Peón
Antonio Peón
HLHeather Lamb
Heather Lamb
AHAlastair R. Hawkins
Alastair R. Hawkins
Concepción González-BelloConcepción González-Bello
Concepción González-Bello
Several 3-alkylaryl mimics of the enol intermediate in the reaction catalyzed by type II dehydroquinase were synthesized to investigate the effect on the inhibition potency of replacing the oxygen atom in the side chain by a carbon atom. The length and the rigidity of the spacer was also studied. The inhibitory properties of the reported compounds against type II dehydroquinase from Mycobacterium tuberculosis and Helicobacter pylori are also reported. The binding modes of these analogs in the active site of both enzymes were studied by molecular docking using GOLD 5.0 and dynamic simulations studies.

6 February 2018 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
CDCuong C. Dang
Cuong C. Dang
APAntonio Peón
Antonio Peón
Pedro BallesterPedro Ballester
Pedro Ballester
Oncology drugs are only effective in a small proportion of cancer patients. Our current ability to identify these responsive patients before treatment is still poor in most cases. Thus, there is a pressing need to discover response markers for marketed and research oncology drugs. Screening these drugs against a large panel of cancer cell lines has led to the discovery of new genomic markers of in vitro drug response. However, while the identification of such markers among thousands of candidate drug-gene associations in the data is error-prone, an appraisal of the effectiveness of such detection task is currently lacking. Here we present a new non-parametric method to measuring the discriminative power of a drug-gene association. Unlike parametric statistical tests, the adopted non-parametric test has the advantage of not making strong assumptions about the data distorting the identification of genomic markers. Furthermore, we introduce a new benchmark to further validate these markers in vitro using more recent data not used to identify the markers. The application of this new methodology has led to the identification of 128 new genomic markers distributed across 61% of the analysed drugs, including 5 drugs without previously known markers, which were missed by the MANOVA test initially applied to analyse data from the Genomics of Drug Sensitivity in Cancer consortium. Discovering markers using more than one statistical test and testing them on independent data is unusual. We found this helpful to discard statistically significant drug-gene associations that were actually spurious correlations. This approach also revealed new, independently validated, in vitro markers of drug response such as Temsirolimus-CDKN2A (resistance) and Gemcitabine-EWS_FLI1 (sensitivity).